Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT03650595

MRI Guided Focal Laser Ablation of Prostate Cancer

Sponsor: University Health Network, Toronto

View on ClinicalTrials.gov

Summary

This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.

Key Details

Gender

MALE

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

102

Start Date

2018-03-29

Completion Date

2028-06-30

Last Updated

2024-08-12

Healthy Volunteers

Conditions

Prostate Cancer Low and Intermediate Risk Prostate Cancer

Interventions

DEVICE

The TRANBERGCLS|Thermal Therapy

MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS\|Thermal Therapy

Inclusion Criteria: * Men 40-80 years of age * Histologically proven low-intermediate risk prostate carcinoma; (Gleason score ≤ 7, primary grade ≤ 4;) * Prostate cancer clinical stage T1c and T2 * MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid TRUS device * Size of MR visible tumor \<20mm * Suspicious site on Prostate MRI must coincide with sector positive for cancer on biopsy * Prostate specific antigen (PSA) level \<15 ng/mL * IPSS, ICIQ-UI-SF, IIEF complete prior to procedure * Life expectancy of greater than 10 years, based on co-morbidity not related to prostate cancer. Exclusion Criteria: * Medically unfit for focal therapy of the prostate * Patients who are unwilling or unable to give informed consent; * Patients who have received androgen suppression therapy * Patients who have received or are receiving chemotherapy for prostate carcinoma; * Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including HIFU, TUNA, RITA, microwave, cryotherapy or any curative treatment * Patients who have undergone radiation therapy for prostate cancer or to the pelvis * Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies); * Patients with a history of noncompliance with medical therapy and/or medical recommendations; * Patients who are unwilling or unable to complete the patient self-assessment questionnaires; * Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition. * Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days; * Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent) * Any condition, or history of illness that, in the opinion of the investigator will confound or increase the patient risk during the study

Locations (1)

Sangeet Ghai, MD

Toronto, Ontario, Canada